JP2017502023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502023A5 JP2017502023A5 JP2016540993A JP2016540993A JP2017502023A5 JP 2017502023 A5 JP2017502023 A5 JP 2017502023A5 JP 2016540993 A JP2016540993 A JP 2016540993A JP 2016540993 A JP2016540993 A JP 2016540993A JP 2017502023 A5 JP2017502023 A5 JP 2017502023A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- macular degeneration
- age
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 239000012634 fragment Substances 0.000 claims 22
- 206010064930 age-related macular degeneration Diseases 0.000 claims 7
- 208000002780 macular degeneration Diseases 0.000 claims 5
- 208000008069 Geographic Atrophy Diseases 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000031471 Macular fibrosis Diseases 0.000 claims 1
- 208000031472 Retinal fibrosis Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000008397 ocular pathology Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920541P | 2013-12-24 | 2013-12-24 | |
| US61/920,541 | 2013-12-24 | ||
| PCT/US2014/049938 WO2015099838A2 (en) | 2013-12-24 | 2014-08-06 | Compositions and methods of treating ocular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017502023A JP2017502023A (ja) | 2017-01-19 |
| JP2017502023A5 true JP2017502023A5 (OSRAM) | 2017-09-14 |
Family
ID=53479755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540993A Pending JP2017502023A (ja) | 2013-12-24 | 2014-08-06 | 眼疾患を治療する組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10183989B2 (OSRAM) |
| EP (1) | EP3086809A4 (OSRAM) |
| JP (1) | JP2017502023A (OSRAM) |
| AU (1) | AU2014370404A1 (OSRAM) |
| CA (1) | CA2934462A1 (OSRAM) |
| WO (1) | WO2015099838A2 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101935088B1 (ko) | 2012-08-24 | 2019-01-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| TWI752012B (zh) | 2016-03-04 | 2022-01-11 | 美商Ｊｎ生物科學有限責任公司 | 針對tigit之抗體 |
| IL299099B2 (en) | 2016-06-27 | 2025-07-01 | Univ California | Cancer treatment combinations |
| WO2019033081A1 (en) * | 2017-08-11 | 2019-02-14 | Massachusetts Eye And Ear Infirmary | INHIBITION OF THE SUPPLEMENTARY ALTERNA PATHWAY FOR THE TREATMENT OF RETINAL ISCHEMIC LESION AND GLAUCOMA |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| BR112020019907A2 (pt) | 2018-04-03 | 2021-01-05 | Ngm Biopharmaceuticals, Inc. | Agentes de ligação a c3 e métodos de uso dos mesmos |
| EP3586865A1 (en) * | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| CN109999015A (zh) * | 2019-04-24 | 2019-07-12 | 江苏省中医药研究院 | 紫草素在制备预防或治疗房颤药物中的用途 |
| CR20220611A (es) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| IL301762A (en) | 2020-10-07 | 2023-05-01 | Line 6 Biotechnology Inc | Methods and materials for the treatment of eye diseases |
| US11981727B2 (en) | 2021-08-31 | 2024-05-14 | Novelmed Therapeutics, Inc | Monospecific and bispecific antibodies and antigen binding fragments thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050044372A (ko) * | 2001-11-09 | 2005-05-12 | 아이테크 파마슈티컬즈, 인크. | 눈의 혈관신생성 질환을 치료하는 방법 |
| EP1931379B1 (en) * | 2005-10-07 | 2013-05-29 | Health Protection Agency | Proteins with improved solubility and methods for producing and using same |
| KR20170002684A (ko) * | 2005-11-04 | 2017-01-06 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
| SG172686A1 (en) | 2006-03-08 | 2011-07-28 | Archemix Corp | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
| US20100015139A1 (en) * | 2008-07-10 | 2010-01-21 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF |
| US9745367B2 (en) * | 2007-03-23 | 2017-08-29 | Novelmed Theraputics, Inc. | Alternative pathway specific antibodies for treating arthritis |
| WO2011112850A2 (en) | 2010-03-10 | 2011-09-15 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-properdin antibodies |
| KR101572700B1 (ko) * | 2007-06-07 | 2015-11-30 | 제넨테크, 인크. | 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법 |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| US20190202898A9 (en) * | 2012-04-03 | 2019-07-04 | Novelmed Therapeutics, Inc. | AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF |
| CN104220453B (zh) * | 2012-04-03 | 2018-03-09 | 诺沃姆德治疗公司 | 人源化的嵌合抗因子c3抗体及其用途 |
| JP6244350B2 (ja) | 2012-04-03 | 2017-12-06 | ノーベルメッド セラピューティクス インコーポレイテッド． | ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用 |
-
2014
- 2014-08-06 EP EP14874978.1A patent/EP3086809A4/en not_active Withdrawn
- 2014-08-06 CA CA2934462A patent/CA2934462A1/en not_active Abandoned
- 2014-08-06 US US15/106,017 patent/US10183989B2/en active Active
- 2014-08-06 JP JP2016540993A patent/JP2017502023A/ja active Pending
- 2014-08-06 WO PCT/US2014/049938 patent/WO2015099838A2/en not_active Ceased
- 2014-08-06 AU AU2014370404A patent/AU2014370404A1/en not_active Abandoned
-
2019
- 2019-01-22 US US16/254,173 patent/US10696740B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502023A5 (OSRAM) | ||
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| PE20240111A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| EA201890834A1 (ru) | Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения | |
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
| WO2014152006A3 (en) | Anti-hepcidin antibodies and uses thereof | |
| WO2014186622A3 (en) | Methods of treatment for guillain-barre syndrome | |
| PH12015501505B1 (en) | Antibodies that bind to tl1a and their uses | |
| WO2018165062A8 (en) | Anti-c5 antibodies and uses thereof | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| JP2018504907A5 (OSRAM) | ||
| EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
| EA201791712A1 (ru) | Антитела к транстиретину | |
| HK1208499A1 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
| MX366359B (es) | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1). | |
| MX2017001959A (es) | Anticuerpos especificos para mmp9. | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
| EA201792220A1 (ru) | Опосредуемая антителом нейтрализация вируса чикунгунья | |
| WO2016057683A3 (en) | Novel anti-nodal antibodies and methods of using same | |
| WO2014062659A3 (en) | Methods of treating ocular diseases | |
| EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
| WO2017079443A8 (en) | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |